Eclampsia primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.

Overview

Detection and management of preeclampsia is critical to reduce the risk of eclampsia. Appropriate management of patients with preeclampsia generally involves the use of magnesium sulfate as an agent to prevent convulsions, and thus preventing eclampsia.

Prevention

Prevention of convulsion is usually done using magnesium sulfate (4-6 g loading dose in 100 ml iv fluid given over 15-20 minutes, then 2g per hour as a continuous infusion).^[1] Evidence for the use of magnesium sulfate came from the international MAGPIE study.^[2]

References

↑ ACOG. “Diagnosis and Management of Preeclampsia and Eclampsia”. ACOG Practice Bulletin # 33, 2002,.
↑ Frayling, Frayling (2004). “The Magpie Trial follow up study: outcome after discharge from hospital for women and children recruited to a trial comparing magnesium sulphate with placebo for pre-eclampsia [ISRCTN86938761]”. 4 (1): 5. PMID 15113445.

Template:WH Template:WS

[ACOG-1] ACOG. “Diagnosis and Management of Preeclampsia and Eclampsia”. ACOG Practice Bulletin # 33, 2002,.

[2] Frayling, Frayling (2004). “The Magpie Trial follow up study: outcome after discharge from hospital for women and children recruited to a trial comparing magnesium sulphate with placebo for pre-eclampsia [ISRCTN86938761]”. 4 (1): 5. PMID 15113445.

[1]

[2]

Eclampsia primary prevention

Overview

Prevention

References

Looking for the patient version?